文献速递消化系统肿瘤

基于免疫检查点抑制剂的降期治疗用于肝细胞癌

Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma.
PubMed 文献 · JAMA Oncol · 2026-10-01

这项多中心回顾性匹配队列研究纳入416例初始超出米兰标准并接受肝移植的肝细胞癌患者,比较基于免疫检查点抑制剂(ICI)的多模式术前策略与不含ICI治疗。结果显示ICI组中位总生存期4.57年、无复发生发期1.47年,均优于非ICI组,但移植后90天内急性排斥反应更常见(16.3% vs 8.2%)。

要点

  • 初始超米兰标准HCC肝移植前用ICI多模式降期与更好的移植后生存相关。
  • ICI组中位OS 4.57年 vs 非ICI组2.53年,中位RFS 1.47年 vs 0.89年。
  • ICI组移植后90天内急性排斥反应发生率更高(16.3% vs 8.2%)。

核心结论

  • 在初始超出米兰标准的肝细胞癌患者中,基于ICI的术前多模式策略与更好的移植后肿瘤学结局和生存相关,但急性排斥反应更常见。

研究设计与样本

  • 共416例匹配受者,ICI组208例(50.5%),非ICI组208例(50.0%),采用倾向评分匹配平衡协变量。

主要发现

  • ICI组中位OS为4.57年(95%CI 4.34至不可估计),非ICI组为2.53年(95%CI 2.17-3.10;P<.001)。
  • ICI组中位RFS为1.47年(95%CI 1.18-4.34),非ICI组为0.89年(95%CI 0.75-1.39;P=.02)。
  • 多变量Cox模型显示ICI策略与更好OS相关(HR 0.63;95%CI 0.43-0.92)和更好RFS相关(HR 0.59;95%CI 0.44-0.80)。
  • Fine-Gray模型显示ICI策略与更低移植后复发风险相关(亚分布HR 0.54;95%CI 0.40-0.72)。
  • 移植后90天内急性排斥反应ICI组34例(16.3%),非ICI组17例(8.2%);P=.01。

临床怎么用

  • 对初始超出米兰标准、拟行肝移植的肝细胞癌患者,可考虑基于ICI的多模式术前降期策略以改善移植后生存。
  • 应用该策略时需警惕移植后急性排斥反应风险增加,并加强监测。

局限性

  • 回顾性队列设计,可能存在残余混杂。
  • 研究仅纳入中国8个高容量中心的患者,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In patients with hepatocellular carcinoma (HCC) that is initially beyond the Milan criteria, immune checkpoint inhibitor (ICI)-based regimens have been explored before liver transplant (LT) to improve tumor control as part of downstaging strategies that most often involve locoregional therapy, but associations with posttransplant oncologic and survival benefit remain uncertain. OBJECTIVE: To evaluate the associations of an ICI-based multimodal pretransplant strategy with posttransplant oncologic outcomes and acute rejection among patients with HCC that was initially beyond the Milan criteria who underwent LT. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, retrospective, matched cohort study included adults (≥18 years) with HCC that was initially beyond the Milan criteria who underwent LT at 8 high-volume LT centers (>55 LTs annually) in China between January 2019 and December 2024. Propensity score matching balanced measured covariates between ICI and non-ICI groups. The data were analyzed in February 2026. EXPOSURES: ICI-based multimodal pretransplant strategy (typically combined with locoregional and/or targeted therapies) vs therapy without ICIs. MAIN OUTCOMES AND MEASURES: Primary outcomes were overall survival (OS) and recurrence-free survival (RFS) from LT. Secondary outcomes were posttransplant recurrence and acute rejection within 90 days. RESULTS: Among 416 matched recipients, 208 (50.5%) received ICI-based multimodal therapy and 208 (50.0%) did not. The median age was 53 years (IQR, 46-59 years), 39 recipients (9.4%) were female, and 377 (90.6%) were male. Median OS was 4.57 years (95% CI, 4.34 to not estimable) in the ICI group and 2.53 years (95% CI, 2.17-3.10; P < .001) in the non-ICI group. Median RFS was 1.47 years (95% CI, 1.18-4.34) in the ICI group and 0.89 years (95% CI, 0.75-1.39; P = .02) in the non-ICI group. In multivariable Cox models, the ICI-based multimodal strategy was associated with better OS (hazard ratio [HR], 0.63; 95% CI, 0.43-0.92) and RFS (HR, 0.59; 95% CI, 0.44-0.80). In a Fine-Gray model, the ICI-based multimodal strategy was associated with lower posttransplant recurrence risk (subdistribution HR, 0.54; 95% CI, 0.40-0.72). Acute rejection within 90 days after transplant was more frequent in the ICI group (34 [16.3%] vs 17 [8.2%]; P = .01). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that an ICI-based multimodal pretransplant strategy was associated with better posttransplant oncologic outcomes and survival in selected patients with HCC that was initially beyond the Milan criteria, despite more frequent acute rejection.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ong M, He K, Wang F, et al. Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma. JAMA Oncol. 2026. PMID: 42821267. doi:10.1001/jamaoncol.2026.3901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。